Defibrillators

Boston Scientific plans to launch the Acuity in July.

The device is the first new Boston Scientific product approved since the Food and Drug Administration lifted restrictions from a warning letter on Monday concerning the company's St.

Paul, Minn.

cardiac rhythm management device plant.

The lifting of restrictions also allowed the approval of five software upgrades for heart devices.

Boston Scientific shares added 2 cents to $16.02 in morning trading on the New York Stock Exchange.

Copyright 2007 Associated Press.

All rights reserved.

This material may not be published, broadcast, rewritten, or redistributed.

Share on digg rawsugar You Might Like Boston Scientific mulls unit IPO Boston Scientific ratings reaffirmed Boston Scientific may spin off stake Boston Scientific's Taxus approved Pharmaceuticals and chemicals highlights to 09:10 GMT Comment on this Article Comment: Title: Name: Please Enter Here Search News Browse ABCmoney News Archive ...

Jude expects to earn between 39 cents and 41 cents per share for the quarter, and $1.70 to $1.75 per share for the year.ANALYST TAKE: Prudential analyst Larry Biegelsen upgraded St.

Jude shares to "Neutral Weight" from "Underweight" in February."In the cardiovascular space, we believe St.

Jude remains the best investment vehicle to play a potential internal cardiac defibrillator market turnaround since the company has limited exposure to the drug-eluting stent market," he wrote in a research note.

Lehman Brothers (nyse: LEH - news - people ) analyst Bob Hopkins said the quarter could be relatively weak, but was optimistic about the second half of the year and 2008."While first-quarter implantable cardiac defibrillator results could be towards the low end of their guidance, we feel St.

Jude's strong new product outlook and scarcity value suggest that at or below current levels the stock looks attractive," he said.WHAT'S AHEAD: St.

Jude products in clinical testing include the Victory IDE and Tendril FSR Model 1699 pacemakers, a post-approval study of a cardiac resynchronization device, and a number of treatments for tachycardia, or rapid heartbeat.The company is repurchasing $1 billion in common stock during the first half of 2007.STOCK PERFORMANCE: St.

Jude shares gai...

"Our Cardiac Rhythm Management group is moving in the right direction with this product approval and yesterday's announcement that the warning letter has been resolved," said Jim Tobin, Boston Scientific's president and CEO.

"We look forward to making this lead available to physicians so they can offer this advanced therapy to their heart failure patients." Boston Scientific said Monday it had resolved issues raised in a 2005 warning letter to Guidant, which it acquired last year.

Del.icio.us RSS © Copyright 2007 United Press International, Inc.

All Rights Reserved.United Press International, UPI, the UPI logo, and other trademarks and service marks, are registered or unregistered trademarks of United Press International, Inc.

in the United States and in other countries.

Post A Comment Your Name Your Email Address Comments Latest Stories Most Popular Popular Videos Va.

Tech student recounts shooting terror Iraq insurgents claim 20 executions Climate change could lead to extinction Neuroticism change tied to mortality rate U.S.

stocks rise on prices, housing news Report: Time Warner may cut cable holdings Keith Olbermann ready for some football Edward Norton to play 'The Hulk' NBA: Utah 130, Portland 93 MLB: Pittsburgh 3, S...